Publication
Title
The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe
Author
Abstract
Cost-effectiveness analyses are usually not directly comparable between countries because of differences in analytical and modelling assumptions. We investigated the cost-effectiveness of rotavirus vaccination in five European Union countries (Belgium, England and Wales, Finland, France and the Netherlands) using a single model, burden of disease estimates supplied by national public health agencies and a subset of common assumptions. Under base case assumptions (vaccination with Rotarix®, 3% discount rate, health care provider perspective, no herd immunity and quality of life of one caregiver affected by a rotavirus episode) and a cost-effectiveness threshold of 30,000, vaccination is likely to be cost effective in Finland only. However, single changes to assumptions may make it cost effective in Belgium and the Netherlands. The estimated threshold price per dose for Rotarix® (excluding administration costs) to be cost effective was 41 in Belgium, 28 in England and Wales, 51 in Finland, 36 in France and 46 in the Netherlands.
Language
English
Source (journal)
Vaccine / International Society for Vaccines. - Amsterdam
Publication
Amsterdam : 2009
ISSN
0264-410X
Volume/pages
27:44(2009), p. 6121-6128
ISI
000271486100005
Full text (Publishers DOI)
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identification
Creation 17.11.2009
Last edited 19.05.2017
To cite this reference